Welcome to our dedicated page for RAPID MICRO BIOSYSTEMS SEC filings (Ticker: RPID), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Rapid Micro Biosystems, Inc. filings document the company's microbial quality-control automation business, governance matters and capital structure. Form 8-K reports furnish operating results, preliminary revenue updates, Regulation FD disclosures about the Growth Direct platform, and material agreements such as term-loan financing secured by company assets and related warrants for Class A common stock.
Proxy filings cover annual meeting procedures, stockholder voting matters, board governance and executive compensation disclosures. Other material-event reports address officer-transition and compensatory-arrangement disclosures, while recent cover pages identify the company as an emerging growth company for Exchange Act reporting purposes.
Rapid Micro Biosystems, Inc. has a significant shareholder position reported by Armistice Capital, LLC and Steven Boyd. The reporting group beneficially owns 3,328,000 shares of Class A common stock, representing 7.29% of the class. All voting and dispositive authority over these shares is reported as shared, with no sole power to vote or dispose. The shares are directly held by Armistice Capital Master Fund Ltd., for which Armistice Capital serves as investment manager under an Investment Management Agreement, and Steven Boyd is the managing member of Armistice Capital. The Master Fund has the right to receive dividends and sale proceeds from the reported securities.
Bain Capital Life Sciences–affiliated funds report their ownership in Rapid Micro Biosystems, Inc. Class A common stock. As of June 30, 2026, Bain Capital Life Sciences Fund, L.P. beneficially owned 7,651,369 shares, representing approximately 16.8% of outstanding Class A shares, and BCIP Life Sciences Associates, LP beneficially owned 783,191 shares, representing approximately 1.7% of outstanding shares.
BCLS Investco, LP holds a Pre-Funded Warrant, a Series A Warrant and a Series B Warrant, each exercisable for up to 1,463,000 Class A shares, but is contractually prohibited from exercising any of these if doing so would cause it and affiliated entities to own more than 9.99% of outstanding Class A shares. Based on Rule 13d-3, these warrants are not deemed beneficially owned. The ownership percentages are calculated from 45,660,027 Class A shares outstanding as of July 31, 2026.
Rapid Micro Biosystems, Inc. reported continued operating losses for the quarter ended June 30, 2026 while modestly growing revenue. Total revenue for the quarter was $8,054 (in thousands), up from $7,262 (in thousands) a year earlier, with $5,049 (in thousands) from recurring consumables and service contracts.
Gross margin improved to $1,212 (in thousands), but operating expenses of $13,534 (in thousands) led to a loss from operations of $12,322 (in thousands) and a quarterly net loss of $12,923 (in thousands). For the first six months of 2026, net loss was $27,198 (in thousands) and operating cash outflows were $27,760 (in thousands). Cash and cash equivalents were $14,687 (in thousands) and short-term investments $5,079 (in thousands), with total assets of $58,450 (in thousands) and stockholders’ equity of $17,748 (in thousands).
Liquidity is supported by a $20,000 (in thousands) term loan under a $45,000 (in thousands) facility with Trinity Capital Inc., bearing interest of 11.0% at June 30, 2026, and by May 2026 related-party equity offerings that raised approximately $8,900 (in thousands) net. The company expects existing cash, investments and anticipated borrowing capacity to fund operations for at least 12 months, assuming revenue growth, gross margin improvement, and cost control.
Rapid Micro Biosystems reported second quarter 2026 total revenue of $8.1 million, up 10.9% from $7.3 million a year earlier. Product revenue was $5.3 million and service revenue $2.8 million. Recurring revenue rose 14.3% to $5.0 million, representing 63% of total revenue, and consumable revenue grew more than 20% year over year. The company placed four new Growth Direct systems, completed nine validations and reached a milestone of 200 Growth Direct systems placed globally.
Total cost of revenue declined to $6.8 million, driving record second-quarter gross margin of 15.0%, up from 3.8% in the prior-year quarter. Operating expenses increased 8.9% to $13.5 million. Net loss was $12.9 million, or $0.27 per share, and non-GAAP adjusted EBITDA loss was $10.3 million. Cash, cash equivalents and short-term investments were approximately $20 million as of June 30, 2026. The company reaffirmed full year 2026 guidance for total revenue of $37.0–$41.0 million and gross margin of approximately 20%, and raised full year system validation guidance to at least 27.
Rapid Micro Biosystems, Inc. director Richard S. Kollender reported exercising stock options covering a total of 3,508 shares of Class A Common Stock on 2026-07-24. The options, described as fully vested and exercisable, were exercised at an exercise price of $0.7500 per share in two tranches of 1,681 and 1,827 underlying shares.
Rapid Micro Biosystems, Inc. reports that President and CEO Robert G. Spignesi Jr. exercised a stock option for 1,402 shares of Class A Common Stock on July 22, 2026 at an exercise price of $0.75 per share. The underlying option, which was fully vested and exercisable and scheduled to expire on August 11, 2026, was fully exercised and no longer remains outstanding. Following this transaction, Spignesi directly holds 1,191,973 shares of Class A Common Stock, with no shares sold in this filing.
RPID affiliate filed a Form 144 reporting an intended sale of 10,000 shares of Class A common stock via stock option exercise, dated 07/08/2026. The filing also lists three reported sales in the past three months: 5,000 shares on 06/10/2026, 3,688 shares on 06/22/2026, and 6,312 shares on 07/01/2026, with the document showing dollar figures adjacent to each sale. The filing shows 41,669,673 (a number listed alongside securities information) dated 07/08/2026.
RPID filed a Rule 144 notice reporting Class A shares to be sold and recent dispositions by an individual holder.
The filing lists 6,312 Class A shares to be sold via a stock option exercise for cash on 07/01/2026. It also records prior sales of 5,000 Class A shares on 06/10/2026 and 3,688 Class A shares on 06/22/2026. Shares outstanding are shown as 41,669,673 as of 07/01/2026.
The filing is a Form 144 notice relating to Class A shares. It lists a Stock Option Exercise disposition on 06/22/2026 with a numeric line item 3688, and reports a prior sale by John Wilson of 5,000 shares on 06/10/2026. The filing names Fidelity Brokerage Services LLC and indicates NASDAQ.
RPID filed a Rule 144 notice for the proposed sale of 5,000 Class A shares dated 06/10/2026. The filing lists the method as a Stock Option Exercise with cash proceeds to the issuer. The filing also reports a prior sale of 9,603 Class A shares on 03/11/2026 for $41,466.71. Shares outstanding were 41,669,673 as of 06/10/2026.